EP2640359A4 - Nouvelles compositions et utilisations d'agents hypotenseurs dans le traitement du cancer - Google Patents

Nouvelles compositions et utilisations d'agents hypotenseurs dans le traitement du cancer

Info

Publication number
EP2640359A4
EP2640359A4 EP11841427.5A EP11841427A EP2640359A4 EP 2640359 A4 EP2640359 A4 EP 2640359A4 EP 11841427 A EP11841427 A EP 11841427A EP 2640359 A4 EP2640359 A4 EP 2640359A4
Authority
EP
European Patent Office
Prior art keywords
cancer therapy
novel compositions
hypertension agents
hypertension
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11841427.5A
Other languages
German (de)
English (en)
Other versions
EP2640359A2 (fr
Inventor
Rakesh Kumar Jain
Yves Boucher
Vikash Pal Singh Chauhan
Benjamin Diop-Frimpong
Stephen Krane
Alan L Crane
Robert Samuel Langer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
XTUIT PHARMACEUTICALS Inc
Original Assignee
General Hospital Corp
XTUIT PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, XTUIT PHARMACEUTICALS Inc filed Critical General Hospital Corp
Publication of EP2640359A2 publication Critical patent/EP2640359A2/fr
Publication of EP2640359A4 publication Critical patent/EP2640359A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
EP11841427.5A 2010-11-18 2011-11-18 Nouvelles compositions et utilisations d'agents hypotenseurs dans le traitement du cancer Withdrawn EP2640359A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41519210P 2010-11-18 2010-11-18
US201161438240P 2011-01-31 2011-01-31
PCT/US2011/061510 WO2012068531A2 (fr) 2010-11-18 2011-11-18 Nouvelles compositions et utilisations d'agents hypotenseurs dans le traitement du cancer

Publications (2)

Publication Number Publication Date
EP2640359A2 EP2640359A2 (fr) 2013-09-25
EP2640359A4 true EP2640359A4 (fr) 2015-11-04

Family

ID=46084685

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11841427.5A Withdrawn EP2640359A4 (fr) 2010-11-18 2011-11-18 Nouvelles compositions et utilisations d'agents hypotenseurs dans le traitement du cancer

Country Status (7)

Country Link
EP (1) EP2640359A4 (fr)
JP (2) JP2014505666A (fr)
CN (1) CN103561726A (fr)
AU (1) AU2011329638C1 (fr)
CA (1) CA2817250A1 (fr)
RU (2) RU2018102375A (fr)
WO (1) WO2012068531A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1583562E (pt) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, compostos relacionados, e suas utilizações
DK2433653T3 (da) 2005-07-15 2019-08-19 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2279008B1 (fr) 2008-04-18 2019-03-06 Angiochem Inc. Compositions pharmaceutiques de paclitaxel, d'analogues de paclitaxel ou de conjugués de paclitaxel et procédés de préparation et d'utilisation correspondants
JP2012505637A (ja) 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド Ｇｌｐ−１アゴニストのコンジュゲート及びその使用
AU2009304505A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
WO2013155493A1 (fr) 2012-04-12 2013-10-17 Yale University Méthode de traitement de maladies et de troubles inflammatoires et auto-immuns
CA2872652A1 (fr) * 2012-05-07 2013-11-14 The General Hospital Corporation Nouvelles compositions et utilisations d'agents antihypertenseurs pour therapie anticancereuse
WO2014054798A1 (fr) 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター Médicament destiné à inhiber une métastase de tumeur maligne
CA2890111A1 (fr) * 2012-11-02 2014-05-08 Pharmacyclics, Inc. Therapie adjuvante par inhibiteur de kinase de la famille tec
WO2014129914A1 (fr) * 2013-02-22 2014-08-28 Auckland Uniservices Limited Procédés de traitement
WO2014134621A2 (fr) * 2013-03-01 2014-09-04 Colorado State University Research Foundation Procédés et compositions permettant d'améliorer une réponse immunitaire, de bloquer la migration des monocytes, d'amplifier l'immunité d'un vaccin et d'inhiber la croissance d'une tumeur et des métastases
US8975290B2 (en) 2013-03-01 2015-03-10 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
WO2014168191A1 (fr) * 2013-04-10 2014-10-16 公立大学法人奈良県立医科大学 Agent prophylactique et/ou thérapeutique pour un carcinome hépatocellulaire
KR20190126452A (ko) 2013-11-01 2019-11-11 예일 유니버시티 면역요법용 모듈러 입자
US9833431B2 (en) * 2013-11-01 2017-12-05 Pitney Pharmaceuticals Pty Limited Pharmaceutical combinations for the treatment of cancer
CN108135939A (zh) * 2015-04-25 2018-06-08 综合医院公司 用于治疗癌症的抗驱走性试剂和免疫治疗剂联合疗法和组合物
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
CN105326812A (zh) * 2015-10-28 2016-02-17 南昌大学 一种索拉菲尼固体脂质纳米粒及其制备方法
WO2017106630A1 (fr) 2015-12-18 2017-06-22 The General Hospital Corporation Polymères polyacétal, conjugués, particules et utilisations associées
US11406684B2 (en) 2016-08-26 2022-08-09 Tetsuji Okuno Fine nano-sized medicinal agent and use thereof
RU2758669C2 (ru) * 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
CN108358995B (zh) * 2017-01-25 2021-07-06 四川大学 CP-iRGD多肽、iDPP纳米粒、载药复合物及其制备方法和应用
RU2724398C1 (ru) * 2019-09-03 2020-06-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ определения степени агрессивности течения рака легкого.
AU2020401226A1 (en) 2019-12-13 2022-06-09 Massachusetts Institute Of Technology Tissue catalyzed growth of polymer as epithelial linings for therapy
EP3842099A1 (fr) 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Utilisation de losartan pour le traitement de maladies fibrotiques, en particulier l'épidermolyse bulleuse
CN112933235A (zh) * 2021-04-07 2021-06-11 北京蛋白质组研究中心 靶向soat1蛋白的化合物在制备预防和/或治疗肝癌药物中的应用
CN115317627B (zh) * 2022-08-26 2023-10-24 江西中医药大学 Abt-510肽在制备肿瘤显像剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
ZA988461B (en) * 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
DE10144980B4 (de) 2001-09-12 2004-06-03 Webasto Vehicle Systems International Gmbh Führungsvorrichtung für einen Deckel eines zu öffnenden Fahrzeugdaches
WO2005102358A2 (fr) * 2004-04-20 2005-11-03 Rnd Pharmaceuticals Compositions pharmaceutiques et methodes d'utilisation de medicaments et de derives de cyclo-oxygenase-2 lipophiles a substitution silicium
AU2005269800B8 (en) 2004-07-19 2011-12-01 Celator Pharmaceuticals, Inc. Particulate constructs for release of active agents
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
JPWO2006077901A1 (ja) 2005-01-20 2008-06-19 塩野義製薬株式会社 Ｃｔｇｆ発現阻害剤
HUE042689T2 (hu) 2005-02-08 2019-07-29 Genzyme Corp TGFbéta elleni antitestek
PL3248600T3 (pl) * 2005-02-18 2020-09-07 Abraxis Bioscience, Llc Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona
WO2007109097A2 (fr) 2006-03-16 2007-09-27 Alnylam Pharmaceuticals, Inc. modulation ARNi des TGF-beta et usages therapeutiques
US20090012052A1 (en) * 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
WO2009105624A2 (fr) * 2008-02-21 2009-08-27 Massachusetts Institute Of Technology Transfert simultané de récepteurs et/ou de co-récepteurs pour la stabilité et l'activité de facteurs de croissance
WO2010005721A2 (fr) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Nanoparticules polymères pharmacologiquement chargées et leurs méthodes de fabrication et d’utilisation
WO2009137543A2 (fr) * 2008-05-06 2009-11-12 Ore Pharmaceuticals Inc. Procédés pour le dépistage et le traitement du cancer du sein
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US20100104645A1 (en) 2008-06-16 2010-04-29 Bind Biosciences, Inc. Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
WO2010068866A2 (fr) 2008-12-12 2010-06-17 Bind Biosciences Particules thérapeutiques pour administration parentérale, et procédés de fabrication et d'utilisation associés
ES2776126T3 (es) 2008-12-15 2020-07-29 Pfizer Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos
DE202009018883U1 (de) 2009-04-24 2014-03-12 BSH Bosch und Siemens Hausgeräte GmbH Programmwähler für ein Hausgerät, insbesondere für eine Waschmaschine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
B. DIOP-FRIMPONG ET AL: "Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 7, 31 January 2011 (2011-01-31), pages 2909 - 2914, XP055176833, ISSN: 0027-8424, DOI: 10.1073/pnas.1018892108 *
JAIN RAKESH K ET AL: "Delivering nanomedicine to solid tumors.", NATURE REVIEWS. CLINICAL ONCOLOGY NOV 2010, vol. 7, no. 11, 14 September 2010 (2010-09-14), pages 653 - 664, XP002744524, ISSN: 1759-4782 *
NOGUCHI RYUICHI ET AL: "Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities", ONCOLOGY REPORTS, vol. 22, no. 2, August 2009 (2009-08-01), pages 355 - 360, XP002744523, ISSN: 1021-335X *
RHODES DANIEL R ET AL: "AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 106, no. 25, 23 June 2009 (2009-06-23), pages 10284 - 10289, XP002592235, ISSN: 0027-8424, [retrieved on 20090601], DOI: 10.1073/PNAS.0900351106 *
See also references of WO2012068531A2 *

Also Published As

Publication number Publication date
EP2640359A2 (fr) 2013-09-25
WO2012068531A2 (fr) 2012-05-24
RU2013127625A (ru) 2014-12-27
RU2018102375A (ru) 2019-02-21
AU2011329638B2 (en) 2016-10-13
CN103561726A (zh) 2014-02-05
JP2014505666A (ja) 2014-03-06
JP2017101056A (ja) 2017-06-08
WO2012068531A3 (fr) 2013-11-28
AU2011329638A1 (en) 2013-05-30
CA2817250A1 (fr) 2012-05-24
AU2011329638C1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
EP2640359A4 (fr) Nouvelles compositions et utilisations d'agents hypotenseurs dans le traitement du cancer
HK1211832A1 (zh) 用於癌症療法的抗高血壓藥物的新穎配方及用法
ZA201300567B (en) Methods and compositions for liver cancer therapy
DK2608777T3 (en) Compositions and Methods for Cardiac Therapy
IL225471A0 (en) Preparations and methods for the prevention and treatment of cancer
PT3023788T (pt) Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores
EP2603202A4 (fr) Compositions et méthodes pour traiter une tauopathie
SG10201508495VA (en) Combination treatment of cancer
IL222291A0 (en) Compositions and methods of synthesis of pyridinoylpiperidine
EP2688594A4 (fr) Procédés et compositions pour le traitement du cancer
IL251083B (en) Compounds and preparations for the treatment of cancer
EP2526118A4 (fr) Compositions et procédés pour le traitement du cancer ovarien
EP2558599A4 (fr) Procédés d'évaluation de réponse à thérapie anticancéreuse
EP2558085A4 (fr) Compositions et procédés pour la prévention et le traitement du cancer
SI2605764T1 (sl) Sestavki za zdravljenje raka
ZA201302952B (en) Fungicidal compositions and methods of use
IL224381B (en) Application of b-functionalized dihydroxy-chlorins for pdt
EP2635273A4 (fr) Compositions d'isoflavonoïdes et méthodes de traitement du cancer
WO2012003421A9 (fr) Compositions et procédés combinatoires de traitement du cancer
EP2547368A4 (fr) Méthodes et compositions pour le traitement du cancer
EP2558113A4 (fr) Compositions thérapeutiques de serca2 et méthodes d'utilisation
EP2637501A4 (fr) Compositions fongicides et procédés d'utilisation
GB201019938D0 (en) Determination of therapeutic agents
GB201017354D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130611

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

R17D Deferred search report published (corrected)

Effective date: 20131128

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1189801

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/14 20060101ALI20150924BHEP

Ipc: A61K 39/395 20060101ALI20150924BHEP

Ipc: A61K 45/06 20060101AFI20150924BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20151002

17Q First examination report despatched

Effective date: 20170309

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20181211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190424

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1189801

Country of ref document: HK